ClinicalTrials.gg
CompletedNCT03774173Updated Aug 9, 2019

Comparison of Aramchol Concentrations With Once or Twice Daily Dosing

A Phase 1 interventional study of Aramchol in Healthy, sponsored by Galmed Pharmaceuticals Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-09.

Sponsored by Galmed Pharmaceuticals Ltd · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The trial is an open-label, 2-period, randomised, crossover study of the plasma concentrations of aramchol, in which subjects will receive oral doses of aramchol at 300 mg twice daily and 600 mg once daily.

Read the detailed description

The trial is an open-label, 2-period, randomised, crossover study of the plasma concentrations of aramchol, in which subjects will receive oral doses of aramchol at 300 mg twice daily (every 12 h) for 9 days in one period, with a single dose in the morning of Day 10, and 600 mg once daily (every 24 h) for 10 days in the other period. A pharmacokinetic profile will be obtained over the dosing interval on Day 10 of each period.

Enrolment of 16 subjects is planned with each subject taking part in the 2 study periods. The subjects will be randomised 1:1 so that 8 subjects receive each regimen in the first period and the alternate regimen in the second period.

Subjects will be screened within 21 days before their first dose of study medicine. In each period they will remain resident on the ward from Day -1 until the morning of Day 11. Subjects will attend a follow-up visit 14 days (±2 days) after the end of the second period. There will be an interval of at least 7 days between Periods 1 and 2.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Galmed Pharmaceuticals Ltd is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female healthy volunteer.
  2. Aged 18-45 years at time of consent.
  3. A (BMI; Quetelet index) in the range 18.0-30.9.
  4. Ability to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
  5. Willingness to give written consent to participate after reading and understanding the information and consent form, and after having the opportunity to discuss the trial with the investigator or his delegate.
  6. Agree to use effective as described in Section 11.
  7. Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication.
  8. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS).

Exclusion criteria

Exclusion Criteria:

  1. Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and not using a reliable method of (see Section 11).
  2. Of East Asian descent including, but not limited to, Chinese, Japanese, Korean, Mongolian, or Vietnamese.
  3. Smoker, or has smoked cigarettes or other tobacco or nicotine products in the last 12 months.
  4. abnormal history, physical findings, , or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.
  5. (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (AP) > at the screening visit. A repeat is allowed on one occasion for determination of eligibility.
  6. Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous.
  7. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs including gastrointestinal disorder or of oesophageal, gastric, biliary or intestinal surgery (excluding herniotomy and appendectomy).
  8. Use of anticholinergic or other drugs known to affect gastrointestinal motility during the 7 days before the first dose of trial medication.
  9. Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness.
  10. Surgery (eg stomach bypass) or medical condition that might affect absorption of medicines.
  11. Presence or history of severe adverse reaction to any drug or a history of sensitivity to aramchol, cholic acid, bile acid sequestrants, or any in the tablets.
  12. Use of a prescription medicine (except oral contraceptives in females), or any other medicine or herbal remedy (including St John's wort) known to interfere with enzymes in the liver, during the 28 days before the first dose of trial medication; or use of any other over-the-counter medicine, with the exception of acetaminophen (paracetamol), during the 7 days before the first dose of trial medication.
  13. Receipt of an product (including prescription medicines) as part of another clinical trial within the 3 months before first admission to this study; in the follow-up period of another clinical trial at the time of screening for this study.
  14. Presence or history of drug or alcohol abuse, or intake of more than 14 units of alcohol weekly.
  15. Blood pressure and heart rate in supine position at the screening examination outside the ranges: blood pressure 100-140 mm Hg systolic, 50-90 mm Hg diastolic; heart rate 45_90 beats/min, unless judged not clinically significant. Borderline values (ie values that are within 5 mm Hg for blood pressure or 5 beats/min for heart rate) will be repeated. Subjects can be included if the repeat value is within range or still borderline, but deemed not clinically significant by the investigator.
  16. Possibility that the volunteer will not cooperate with the requirements of the protocol.
  17. Evidence of drug abuse on urine testing.
  18. Positive test for , or .
  19. Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood donor.
  20. Objection by GP to volunteer entering trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Aramchol 300 mg

    Aramchol 300 mg twice daily (every 12 hours)

    Drug: Aramchol

  • Experimental
    Aramchol 600 mg

    Aramchol 600 mg once daily (every 24 hours)

    Drug: Aramchol

Interventions

  • One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of aramchol

    AUC

    Time frame: PK parameters will be measured on Days 7, 8 , 9, and 10.

  2. Pharmacokinetics of aramchol

    Cavg

    Time frame: PK parameters will be measured on Days 7, 8 , 9, and 10.

  3. PK of aramchol

    Ctau

    Time frame: PK parameters will be measured on Days 7, 8 , 9, and 10.

  4. Pharmacokinetics (PK) of aramchol

    Tmax

    Time frame: K parameters will be measured on Days 7, 8 , 9, and 10.

Secondary outcomes

  1. Vital signs and physical examination

    Systolic and diastolic blood pressure, Heart rate, Oral temperature and Respiratory rate

    Time frame: During both treatment periods vital signs will be assessed on Days 1, 5 and 10.

  2. Electrocardiogram

    12-lead ECGs

    Time frame: During both treatment periods ECG will be assessed on Days 1, 5 and 10.

  3. Laboratory safety tests: Biochemistry

    Usual tests.

    Time frame: On Day -1, Day 5,on Day 11.

  4. Laboratory safety tests: Hematology

    haemoglobin, red blood cells, mean corpuscular volume , mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, haematocrit, white blood cells and platelets.

    Time frame: On Day -1, Day 5,on Day 11.

  5. Laboratory safety tests: Urinalysis

    Usual Dipstick test

    Time frame: On Day -1, Day 5,on Day 11.

  6. Safety and tolerability: Adverse events (AEs).

    Adverse events are collected during entire study period.

    Time frame: From screening visit to 14 days after the last dose in period 2.

07

Study locations

1 site
  • Hammersmith Medicines Research (HMR)
    London, NW10 7EW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Feb 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2018
First posted
Dec 12, 2018
StartActual
Dec 8, 2018
Primary completionActual
Feb 3, 2019
CompletionActual
Mar 5, 2019
Last update
Aug 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03774173
Lead sponsor
Galmed Pharmaceuticals Ltd
Collaborators
Hammersmith Medicines Research, Analyst Research Laboratories, Diamond Pharma Services Regulatory Affairs Consultancy
Responsible party
Sponsor
First posted
Dec 12, 2018
Start date
Dec 8, 2018
Primary completion
Feb 3, 2019
Completion
Mar 5, 2019
Last update
Aug 9, 2019

Study contacts

Adeep Puri, M.D.
principal investigator · Hammersmith Medicines Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aramchol

Start the discussion